James Hadfield

Director and Principal Diagnostic Scientist
AstraZeneca

Dr James Hadfield leads the search for, and development of, innovative diagnostic assays and technologies for MDx, TDx and PDx working through collaborations and partnering with academia and industry. Previously he led the Genomics Core at University of Cambridge’s CRUK Cambridge Institute, he is seconded with Genomics England, and has consulted widely on genomics technologies. He has worked with genomics technologies, especially NGS, for the past 10-15 years. He was awarded PhD at UEA and has co-authored multiple influential papers in cancer genomics including one of the largest genomic studies of Breast Cancer (Nature 2012), some of the first reports of ctDNA liquid biopsy: using amplicons (STM 2012) or exomes (Nature 2013) and developed a sWGS CNV pipeline for exome sequencing (Cell 2016).